摘要
我们社会的日益全球化不仅带来了世界范围的一体化,也增加和促进了我们接触新的病毒病原体,对我们的全球健康产生了明显的影响。特别是随着SARS-CoV-2的出现,我们的生物医学研究基础设施从未像现在这样迫切地需要快速开发抗病毒方案,以证明对这些病原体的疗效有所提高。在这里,我们展示了针对RNA病毒的RNA依赖性RNA聚合酶(RdRP)这一有利可图的目标的3种尖锐抗病毒药物。鉴于目前抗击COVID-19的努力,RdRP是一个及时且相关的主题。虽然针对RdRP的有效药物设计很重要,但它们作为一种护理标准的益处和潜力真正依赖于它们在精心设计的临床试验中脱颖而出。
关键词: 抗病毒药物,病毒,瑞德西韦,利巴韦林,法比拉韦,SARS-CoV-2, COVID-19。
Current Medicinal Chemistry
Title:Targeting Viral RNA-Dependent RNA Polymerases as an Antiviral Therapy
Volume: 28 Issue: 40
关键词: 抗病毒药物,病毒,瑞德西韦,利巴韦林,法比拉韦,SARS-CoV-2, COVID-19。
摘要: Progressive globalization of our society brings not only worldwide integration, it also increases and promotes our exposure to new viral pathogens with evident impacts on our global health. Especially with the emergence of SARS-CoV-2, our biomedical research infrastructure has never been more compelled to rapidly develop antiviral regimens that demonstrate improved efficacy against these pathogens. Here, we showcase 3 poignant antivirals against the lucrative target, RNA-dependent RNA polymerase (RdRP) of RNA viruses – a timely and relevant topic given the present efforts against COVID-19. While effective drug designs against RdRP are important, their benefit and potential as a standard of care truly relies on them standing out in well-designed clinical trials.
Export Options
About this article
Cite this article as:
Targeting Viral RNA-Dependent RNA Polymerases as an Antiviral Therapy, Current Medicinal Chemistry 2021; 28 (40) . https://dx.doi.org/10.2174/0929867328666210204205726
DOI https://dx.doi.org/10.2174/0929867328666210204205726 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements